Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ: ANIP) insider transactions

In the twelve months to 10 November 2026, executives and directors of ANI Pharmaceuticals reported 50 open-market sales of 200,229 shares ($15.7m) and 0 open-market purchases, by 12 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in ANI Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
29 October 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−2,850$72.87166,143Form 4
15 October 2026Lalwani NikhilPresident & CEOOpen-market sale, 10b5-1 plan−5,400$71.89333,689Form 4
13 October 2026Cook MeredithSr. VP, General Counsel & Sec.Open-market sale, 10b5-1 plan−500$73.5973,424Form 4
29 September 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−2,850$73.00168,993Form 4
15 September 2026Lalwani NikhilPresident & CEOOpen-market sale, 10b5-1 plan−5,400$71.00339,089Form 4
14 September 2026Cook MeredithSr. VP, General Counsel & Sec.Open-market sale, 10b5-1 plan−500$70.7973,924Form 4
11 September 2026Thoma JeanneDirectorOpen-market sale, 10b5-1 plan−1,000$71.5326,762Form 4
31 August 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−2,850$72.80171,843Form 4
25 August 2026Lalwani NikhilPresident & CEOOpen-market sale, 10b5-1 plan−5,400$74.30344,489Form 4
19 August 2026Gosebruch Henry ODirectorGrant or award+6,662—6,662Form 4
13 August 2026Cook MeredithSr. VP, General Counsel & Sec.Open-market sale, 10b5-1 plan−500$75.4874,424Form 4
10 August 2026Gutwerg OriSVP, GenericsOpen-market sale−3,162$77.0075,534Form 4
29 July 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−2,850$81.36174,693Form 4
18 July 2026Cook MeredithSr. VP, General Counsel & Sec.Shares withheld for tax−2,466$79.2074,924Form 4
13 July 2026Cook MeredithSr. VP, General Counsel & Sec.Open-market sale, 10b5-1 plan−500$81.8477,390Form 4
2 July 2026Carey Stephen P.SVP & CFOOption exercise, 10b5-1 plan+3,313$49.51180,856Form 4
2 July 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−3,313$86.00177,543Form 4
29 June 2026Carey Stephen P.SVP & CFOOpen-market sale, 10b5-1 plan−2,850$84.12177,543Form 4
12 June 2026Cook MeredithSr. VP, General Counsel & Sec.Open-market sale, 10b5-1 plan−500$82.0377,890Form 4
8 June 2026Haughey ThomasDirectorOpen-market sale, 10b5-1 plan−2,000$80.8838,878Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ANI Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.